Severe Late-Onset Drug-Induced Immune Thrombocytopenia Following IFN β-1a Treatment: A Case Report of a 52-Year-Old Woman with Relapse-Remitting Multiple Sclerosis.

Détails

Ressource 1Télécharger: 36467669_BIB_A48F4C0C1B5F.pdf (252.60 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_A48F4C0C1B5F
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Institution
Titre
Severe Late-Onset Drug-Induced Immune Thrombocytopenia Following IFN β-1a Treatment: A Case Report of a 52-Year-Old Woman with Relapse-Remitting Multiple Sclerosis.
Périodique
Case reports in hematology
Auteur⸱e⸱s
Cisarovsky C., Théaudin M., Bart P.A., Stalder G., Alberio L.
ISSN
2090-6560 (Print)
ISSN-L
2090-6579
Statut éditorial
Publié
Date de publication
2022
Peer-reviewed
Oui
Editeur⸱rice scientifique
Konstantopoulos Kostas
Volume
2022
Pages
2767031
Langue
anglais
Notes
Publication types: Case Reports
Publication Status: epublish
Résumé
Interferon β-1a (IFNβ1a) is considered safe in relapsing-remitting multiple sclerosis (RRMS). Drug-induced thrombocytopenia (DITP) is a rare but underreported adverse event that is often confused with other causes of thrombocytopenia. We report the case of a 52-year-old woman who developed limb and oral mucosa petechiae and hematochezia, 10 years after beginning IFNβ1a. Blood work showed an isolated severe thrombocytopenia and ruled out other autoimmune diseases, viral infections, intravascular hemolysis, and renal impairment. Oral corticosteroids and tranexamic acid were initiated with a favorable platelet response. IFNβ1a was resumed, leading to recurrence of thrombocytopenia. Platelets came back to normal after intravenous immunoglobulins and IFNβ1a was definitively discontinued. To our knowledge, this is the first case of drug-induced immune thrombocytopenia (DITP) associated with IFNβ1a.
Mots-clé
Applied Mathematics
Pubmed
Web of science
Open Access
Oui
Création de la notice
25/11/2022 18:21
Dernière modification de la notice
23/01/2024 7:31
Données d'usage